Wednesday, August 10, 2011

Gilead wins FDA approval of new HIV combo treatment

The Food and Drug Administration approved a new combination HIV treatment that includes Gilead Sciences ’ Truvada and another antiretroviral drug, Edurant.
Foster City-based Gilead (NASDAQ: GILD) makes Truvada, which is a combination of two drugs -- emtricitabine and tenofovir disoproxil fumarate. In this new treatment, Truvada is combined with Edurant (rilpivirine) in a single tablet aimed at HIV-1 patients who are “treatment-naïve,” meaning they have not taken HIV treatment before.
The new combination pill is called Complera.

No comments:

Post a Comment